Successful registration requires more than submitting a dossier. The decisions made before submission can shape timing, cost and long-term market access.
Choosing the wrong pathway: Classification, intended use and claims determine which authority and evidence package apply.
Underestimating document preparation: Missing, inconsistent or outdated records create avoidable authority questions.
Selecting a partner for registration only: The local structure should support the company’s regulatory and commercial plans after approval.
Assuming another market’s dossier is sufficient: UAE expectations may require local adaptations to documents, artwork or administrative evidence.
Treating approval as the finish line: Pricing, pharmacovigilance, post-approval maintenance, coding, insurance coverage and launch planning all need ownership.
A pathway assessment and readiness review at the start can prevent expensive corrections later and create a stronger foundation for sustainable market entry.
Medical Devices 4 min read
UAE medical device registration in 2026
Manufacturers need a clear EDE strategy that connects classification, local representation, technical evidence and post-market responsibilities.
Confirm the device risk class and the registration route before preparing the submission.
Establish the appropriate UAE Local Authorized Representative and communication structure.
Align quality certificates, approvals, labeling and the technical dossier across all submitted records.
Plan for licensing, import requirements and market availability beyond the initial approval.
Maintain compliance through renewals, change notifications, vigilance and post-market surveillance.
Early classification and a structured evidence gap assessment can reduce unnecessary delays while making future lifecycle work easier to manage.
Healthcare Compliance 4 min read
Healthcare cybersecurity is part of patient safety
As care becomes more digital, protecting health information is a clinical, operational and governance priority—not only an IT task.
The Abu Dhabi Healthcare Information and Cyber Security Standard (ADHICS) provides a framework for healthcare organizations handling sensitive information. Its practical focus includes confidentiality, integrity and availability of data; risk-based governance; access control; incident response; business continuity; and continuous monitoring.
Organizations should connect security with operations
Define ownership across leadership, clinical, technology and compliance teams.
Assess risks introduced by connected devices, cloud services, AI and third-party access.
Test incident-response and recovery plans before an event occurs.
Strong cyber resilience protects continuity of care and reinforces the patient trust on which digital healthcare depends.
Health Technology Assessment 5 min read
Abu Dhabi HTA: demonstrating value beyond approval
Market access increasingly depends on proving meaningful value, not regulatory approval alone.
Health Technology Assessment brings clinical evidence together with cost-effectiveness, budget impact, equity, ethics and long-term value. This is particularly relevant to innovative pharmaceuticals, advanced therapies, medical devices, digital health, AI-enabled technologies and other high-cost interventions.
Build the evidence plan early
Identify the patient population and the unmet need the technology addresses.
Define outcomes that are meaningful to clinicians, patients and payers.
Prepare health-economic and budget-impact evidence alongside the clinical story.
Connect the value proposition to coding, reimbursement and implementation planning.
Companies that coordinate regulatory, medical, HEOR and market-access work earlier are better placed to answer the questions that follow approval.
Market Access 4 min read
Solving coding and insurance barriers across the Emirates
A product can be registered and still remain commercially inaccessible if coding and reimbursement are addressed too late.
Before launch, companies should map the requirements for DOH or DHA coding, hospital and payer onboarding, reimbursement evidence and the information insurers need to assess coverage. The pathway can differ between Abu Dhabi, Dubai and other emirates, and problems often arise when regulatory, pricing, coding and commercial teams work separately.
A practical access plan should cover
The correct product, service or procedure coding route.
Evidence required for payer and provider review.
Ownership of follow-up when coverage or claims are rejected.
A realistic timeline linking approval, coding, stocking and launch.
Starting this work early helps prevent the common gap between regulatory approval and real patient access.
